June 21, 2022Open Access
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
View Full Paper
Ask AI
Bookmark
Share
Key result
Stage III breast cancer is linked to ~22% higher PCSK9 levels versus benign lesions.
- P<0.05
- n=46
Why the study?
Circulating levels of the targets of a new generation of lipid-lowering drugs, including PCSK9, ANGPTL3, and Lp(a), have not been fully investigated in cancers.
Are circulating levels of PCSK9, ANGPTL3, and Lp(a) altered in women with stage III breast cancer compared to those with benign or premalignant breast lesions?
Comparison
Stage III breast cancer vs premalignant or benign breast lesions
Design
Age-matched case-control study
Authors
Discussion
Loading...
Member takes
Implication
Should not change practice; leaves open a PCSK9 link to breast cancer progression pending prospective validation.
Study Design
Type
Case-Control (n=46)
Multicenter
No
Structured PICO
Are circulating levels of PCSK9, ANGPTL3, and Lp(a) altered in women with stage III breast cancer compared to those with benign or premalignant breast lesions?
P
Population
46 women, including 23 with stage III breast cancer (ductal, lobular, or mixed) and 23 age-matched controls with premalignant (stage 0, n=9) or benign (n=14) breast lesions.
C
Comparator
Women with premalignant (stage 0) or benign breast lesions.
O
Outcome
Circulating levels of PCSK9, ANGPTL3, and Lp(a)surrogate
Main Result
Absolute Event Rate: 95.9% vs 78.5%
p-value: p=<0.05
Circulating PCSK9 levels are elevated in women with stage III breast cancer compared to those with benign lesions, suggesting a potential role for PCSK9 in breast cancer progression.
Limitations
- Limited amount of plasma samples
- Merging of non-cancerous samples with early-stage cancerous samples to form a control group
- Information on medications such as statins was unknown
- Ethnical origins of women were not documented
- Small sample size (cohort of 46 women)
- Insufficient power to detect changes in the lipid profile
Cite This Study
Chong et al. (2022) conducted a case-control in Stage III breast cancer (n=46). Stage III breast cancer vs. Benign breast lesion was evaluated on PCSK9 levels (ng/mL) (p=<0.05). PCSK9 levels were significantly higher in women with stage III breast cancer compared to age-matched counterparts presenting a benign lesion (95.9 vs 78.5 ng/mL, p<0.05).
View Full Paper
Ask AI
Bookmark
Share